Leadership & Pay ·
MindWalk appoints three senior leaders from Pfizer and Novartis to strengthen preclinical development
HYFTMindWalk Holdings Corp.
MindWalk Holdings Corp. announced the appointment of three senior executives to its Boston-based leadership team as its pipeline advances toward preclinical efficacy studies. Zachary Maben joins as Director, Antigen Discovery & Protein Engineering from Arbor Biotechnologies and previously Pfizer. Joanne Lim arrives as Director, Preclinical Development from Orum Therapeutics and previously Novartis. Shuji Sato expands his responsibilities to include the Company’s pipeline. MindWalk Holdings Corp. is a Bio-Native AI company building biological intelligence infrastructure for drug discovery.